Maxion Therapeutics

About Maxion Therapeutics

Maxion Therapeutics is focused on discovering transformational therapies using their proprietary KnotBody® technology. They aim to create first-in-class and best-in-class protein therapeutics for treating previously untreatable ion channel and GPCR-driven diseases, addressing significant unmet medical needs in areas like chronic pain, autoimmunity, and cardiovascular disease.

Products & Services

KnotBody® Technology:A revolutionary platform that combines naturally occurring cysteine-rich miniproteins (Knottins) with antibody engineering to target ion channels and GPCRs, offering superior selectivity, potency, multifunctionality, and manufacturability for developing safe, efficacious, and long-acting drugs against undruggable targets.

KnotBody technology: A revolutionary platform that fuses cysteine-rich miniproteins (knottins) into antibody binding loops to create first-in-class and best-in-class protein therapeutics for ion channel and GPCR-driven diseases, offering superior potency, selectivity, multifunctionality, half-life, and manufacturability.

Specialties

Ion Channel Drug Discovery GPCR Drug Discovery Protein Therapeutics Antibody Engineering Protein therapeutics Antibody engineering Ion channel and GPCR drug discovery

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 72000000 MR: - FA: $72 million (£58 million) FAN: 72000000	D: 2025-03-17 FD: 2025-03-17	7 investors
2	RT: Series A T: - FT: Series A	A: 16000000 MR: - FA: $16 million FAN: 16000000	D: 2023-02-15 FD: 2023-02-15	3 investors

Series A Latest

2025-03-17

$72.0M

7 investors (Pro only)

Series A 2023-02-15

$16.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Arndt Schottelius

CEO

LinkedIn (Pro only)

J

John McCafferty

Co-founder and CTO

LinkedIn (Pro only)

A

Aneesh Karatt-Vellatt

Co-founder and CSO

LinkedIn (Pro only)

E

Eva-Lotta Allan

Independent Chair

L

Lucy Edwardes Jones

Non-Executive Director BGF

T

Tim Funnell

Non-Executive Director Monograph Capital

View 9 more team members with Pro

Unlock Full Team Directory

Recent News